JOHN VIERLING to Cholestasis
This is a "connection" page, showing publications JOHN VIERLING has written about Cholestasis.
Connection Strength
0.231
-
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis. Aliment Pharmacol Ther. 2024 01; 59(2):186-200.
Score: 0.175
-
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis. N Engl J Med. 2024 02 29; 390(9):795-805.
Score: 0.044
-
Limited role for CXC chemokines in the pathogenesis of alpha-naphthylisothiocyanate-induced liver injury. Am J Physiol Gastrointest Liver Physiol. 2004 Sep; 287(3):G734-41.
Score: 0.011